Metastatic SDHB-Mutated Paraganglioma: MIBG, Sunitinib, or Belzutifan First
A single patient whose known genetic mutation shapes not just her prognosis but which of three real treatment options actually fits her tumor's specific biology.
Ana Luisa F., a 34-year-old graphic designer, has known she carries a germline SDHB mutation since her mother's own paraganglioma diagnosis prompted family testing eight years ago, and has lived since then with the specific, low-grade dread of exactly this appointment. A retroperitoneal paraganglioma resected two years ago has recurred, now with confirmed bone and liver metastases — metastatic disease that, in SDHB carriers specifically, occurs roughly half the time, far more often than in sporadic cases. She is otherwise well, working full time, and wants to understand not just which treatment is best in general but which one actually fits a disease her own genetics already shape in a specific, real way.
That specificity matters more here than it does for most cancers, because SDHB-mutated tumors belong to what's called the pseudohypoxic cluster, a distinct molecular biology that several current treatment options are now built around exploiting. Sunitinib is the only agent tested in a randomized, placebo-controlled trial — FIRSTMAPPP, 78 patients — which met its primary endpoint (36% progression-free at 12 months versus 19% on placebo) and found an even stronger 50% response rate specifically in its SDHB-mutated subgroup, described by the trial's own investigators as direct clinical validation of the pseudohypoxic mechanism. 131I-MIBG therapy remains a real option if her tumor demonstrates avidity on diagnostic scanning, historically showing meaningful disease control as a systemic radiotherapeutic rather than a daily oral drug. And belzutifan, a HIF-2α inhibitor approved in 2025 as the first oral targeted therapy for this disease, was built specifically around the pseudohypoxic pathway SDHB mutations drive — mechanistically the most direct fit for her tumor's own biology, but with far less mature clinical evidence behind it than sunitinib's randomized trial.
Systemic therapy planning, medical and nuclear oncology
FIRSTMAPPP is the only randomized, placebo-controlled trial we have in this disease, and its SDHB-mutated subgroup showed a 50% response rate — the investigators themselves called that direct clinical validation of the pseudohypoxic mechanism her tumor runs on. I'd start sunitinib now rather than wait on a scan result to make a decision the trial data already supports strongly.
I don't dispute the FIRSTMAPPP result. But her MIBG scan is pending and will tell us, directly and specifically, whether a different modality entirely — a systemic radiotherapeutic rather than an indefinite daily drug — is even on the table. That's not a hypothetical population-level argument, it's a fact about her specific tumor we're a few days from knowing. Starting sunitinib today doesn't cost her the option later, but it does mean committing to daily dosing before we've looked at information already in motion.
I'm not proposing we wait indefinitely — just long enough for a result that's already ordered and genuinely changes the picture if it comes back positive.
Belzutifan is worth naming here too — mechanistically, it's the most direct fit for SDHB-driven pseudohypoxic biology of anything available, since it targets the pathway her mutation actually drives. But it's new enough that its evidence base isn't in the same category as FIRSTMAPPP's randomized data yet, and I don't think "mechanistically elegant" should be confused with "clinically proven." I'd get the MIBG result first — if it's avid, that's a genuinely different treatment path worth taking; if it isn't, we choose between sunitinib's stronger evidence and belzutifan's stronger mechanistic fit with her eyes open about what each one actually rests on.
Agreed: await the pending MIBG scan result before starting systemic therapy, with sunitinib as the planned next step if the tumor is non-avid, given its randomized trial evidence and SDHB-specific response signal.
Not agreed: whether belzutifan should be tried before sunitinib if MIBG isn't an option, given how directly it targets her tumor's actual genetic mechanism. The pharmacologist and medical oncologist differ on how much weight a strong mechanistic rationale should carry against a more mature but less genotype-specific randomized trial, and left that question for a joint decision once the scan result is known.